LONDON (Alliance News) - Generic veterinary medicine supplier, Animalcare Group PLC Tuesday said that trading in the first four months of the year is ahead of the prior year, and in line with management expectations.
In an annual general meeting statement, Chairman James Lambert said that the new product development pipeline has maintained momentum, following the launch in the first quarter of the enhanced Phenoleptil, a product used to prevent epileptic seizures in dogs.
Lambert also said that preparations are in place for the launch of two companion animal medicines in the second quarter of the year.
Animalcare shares were down 3.4% Tuesday morning, trading at 172.00 pence per share.
By Rowena Harris-Doughty; rowenaharrisdoughty@alliancenews.com; @rharrisdoughty
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Animalcare Grp (ANCR)